RSLV-132 ( DrugBank: - )

---

2 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
49	全身性エリテマトーデス	2
53	シェーグレン症候群	2

49. 全身性エリテマトーデス

---

臨床試験数 : 993 /  薬物数 : 702 - (DrugBank : 184) / 標的遺伝子数 : 116 - 標的パスウェイ数 : 200

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02660944 (ClinicalTrials.gov)	January 3, 2016	16/1/2016	A Phase 2a of RSLV-132 in Subjects With Systemic Lupus Erythematosus (SLE)	A Phase 2a, Double-blind, Placebo-Controlled Study of RSLV-132 in Subjects With Systemic Lupus Erythematosus (SLE)	Systemic Lupus Erythematosus	Drug: RSLV-132;Drug: Placebo	Resolve Therapeutics	NULL	Completed	18 Years	70 Years	All	64	Phase 2	United States
2	NCT02194400 (ClinicalTrials.gov)	July 2014	16/7/2014	Dose Escalation Study of RSLV-132 in Subjects With Systemic Lupus Erythematosus	A Double-Blind, Placebo-Controlled Dose Escalation Study of the Administration of Multiple Intravenous Doses of RSLV-132 in Subjects With Systemic Lupus Erythematosus	Systemic Lupus Erythematosus	Biological: RSLV-132	Resolve Therapeutics	NULL	Completed	18 Years	70 Years	Both	32	Phase 1	United States

53. シェーグレン症候群

---

臨床試験数 : 305 /  薬物数 : 325 - (DrugBank : 104) / 標的遺伝子数 : 58 - 標的パスウェイ数 : 188

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03247686 (ClinicalTrials.gov)	February 1, 2017	3/8/2017	A Study of RSLV-132 in Subjects With Primary Sjogren's Syndrome	A Phase 2, Double-blind, Placebo-controlled Study of RSLV-132 in Subjects With Primary Sjogren's Syndrome	Sjogren's Syndrome	Drug: RSLV-132;Drug: Placebo	Resolve Therapeutics	University Hospital Birmingham;Newcastle-upon-Tyne Hospitals NHS Trust	Completed	18 Years	70 Years	All	28	Phase 2	United Kingdom
2	EUCTR2016-001586-87-GB (EUCTR)	29/09/2016	06/07/2016	A Phase 2 Study of RSLV-132 in Subjects with Sjogren’s Syndrome	A Phase 2, Double Blind, Placebo Controlled Study of RSLV-132 in Subjects with Primary Sjogren’s Syndrome - RSLV-132 in Primary Sjogren’s Syndrome	Primary Sjogrens Syndrome;Therapeutic area: Body processes [G] - Immune system processes [G12]	Product Name: RSLV-132	Resolve Therapeutics, LLC	NULL	Not Recruiting			Female: yes Male: yes	28	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no	United Kingdom